DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.

Author(s): Guinea J, Recio S, Pelaez T, Torres-Narbona M, Bouza E

Affiliation(s): Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Maranon, Universidad Complutense de Madrid, Madrid, Spain. jguineaortega@yahoo.es

Publication date & source: 2008-09, Antimicrob Agents Chemother., 52(9):3444-6. Epub 2008 Jul 7.

Publication type: Research Support, Non-U.S. Gov't

We studied the activity of voriconazole against 400 clinical strains of Aspergillus from the pre-voriconazole (1999 to 2002) and post-voriconazole (2003 to 2007) periods. Although the mean MICs of strains from the post-voriconazole period were slightly higher (0.39 versus 0.57 microg/ml; P < 0.001), all strains were susceptible to voriconazole and presented an MIC of <or=2 microg/ml.

Page last updated: 2008-11-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017